Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6141021 | 0.78 | CYP3A4 (0.40) | CYP3A4HIF1AMAPTALDH1A1KMT2A | |
| SCHEMBL1874935 | 0.78 | GABRA1 (0.58) | GABRA1GABRB2TSHRPOLBLMNA | |
| SCHEMBL11208061 | 0.77 | GABRA1 (0.50) | GABRA1GABRB2TSHRPOLBLMNA | |
| SCHEMBL5424279 | 0.77 | GABRA1 (0.56) | GABRA1GABRB2TSHRPOLBLMNA | |
| SCHEMBL27568004 | 0.77 | GABRA1 (0.95) | GABRA1GABRB2TSHRPOLBLMNA | |
| SCHEMBL4429090 | 0.76 | GABRA1 (0.48) | GABRA1GABRB2TSHRPOLBLMNA | |
| SCHEMBL9165861 | 0.76 | ESR1 (0.46) | GABRA1GABRB2TSHRLMNASLC6A2 | |
| SCHEMBL910441 | 0.76 | ESR1 (0.46) | GABRA1GABRB2TSHRLMNASLC6A2 | |
| SCHEMBL9210107 | 0.75 | GABRA1 (0.54) | GABRA1GABRB2TSHRPOLBLMNA | |
| SCHEMBL9290334 | 0.75 | GABRA1 (0.65) | GABRA1GABRB2TSHRPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635878-A2 | PEPTIDE CONJUGATE FOR MAGNETIC RESONANCE IMAGING | GUERBET (FR) | 2006-03-22 | — | — | EP | claimed |
| WO-2004112840-A2 | PEPTIDE CONJUGATE FOR MAGNETIC RESONANCE IMAGING | GUERBET (FR) | 2004-12-29 | — | — | WO | claimed |
| US-4563305-A | QUANTITATIVE ANALYSIS | UNIVERSITY OF MIAMI (US) | 1986-01-07 | — | — | US | claimed |
| EP-0056015-A1 | Radiolabelled substrates for assaying mammalian enzymes | Ryan, James Walter (US) | 1982-07-14 | — | — | EP | claimed |
| CN-111329775-A | Isobutyramide derivative and use thereof | 福建莲珂科技有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-1370276-B1 | INTERCELLULAR COMMUNICATION FACILITATING COMPOUNDS AND THEIR MEDICAL USE | ZEALAND PHARMA AS (DK) | 2011-02-09 | — | — | EP | disclosed |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7737113-B2 | Cyclic and linear oligopeptides; capable of increasing gap junction conductance; lack the proarrhythmic side effects; use as drug to also treat eye disorders, cancer, and gastrointestinal disorders among others | ZEALAND PHARMA A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| EP-0056015-A1 | Radiolabelled substrates for assaying mammalian enzymes | Ryan, James Walter (US) | 1982-07-14 | — | — | EP | disclosed |
| EP-0056015-A1 | Radiolabelled substrates for assaying mammalian enzymes | Ryan, James Walter (US) | 1982-07-14 | — | — | EP | disclosed |
| EP-0015059-B1 | IMMUNOCHEMICAL CONJUGATES: METHOD AND COMPOSITION | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1982-06-30 | — | — | EP | disclosed |
| US-4276206-A | GENERALLY APPLICABLE METHOD OF MAKING IMMUNOSUPPRESSIVE AGENTS | SCRIPPS CLINIC & RESEARCH FOUNDATION (US) | 1981-06-30 | — | — | US | disclosed |
| US-4253995-A | PURIFICATION BY REACTING WITH BIOTIN AND SEPARATING ON AVIDIN COLUMN | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1981-03-03 | — | — | US | disclosed |
| US-4253996-A | MALEIMIDE DERIVATIVE AS COUPLER FOR POLYPEPTIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1981-03-03 | — | — | US | disclosed |
| EP-0015059-A2 | Immunochemical conjugates: method and composition | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1980-09-03 | — | — | EP | disclosed |
| US-4220565-A | Immunochemical conjugates: method and composition | SCRIPPS CLINIC & RESEARCH FOUNDATION (US) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | GABRA1 4400/4885GABRB2 3764/4885TSHR 4711/4885 |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | CUTA, GLRA3, ARGLU1 | GABRA1 883/4885GABRB2 375/4885TSHR 2401/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | GABRA1 1620/4885GABRB2 899/4885TSHR 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.